Literature DB >> 9538634

A case of chronic graft-versus-host-disease following allogeneic peripheral blood stem cell rescue for poor graft function after bone marrow transplantation.

H J Kim1, I J Chung, J J Lee, J S Seo, M R Park, K S Choi, H Kook, T J Hwang.   

Abstract

To overcome poor graft function after allogeneic bone marrow transplantation (BMT), the use of peripheral blood stem cells (PBSC) instead of bone marrow is gaining more popularity because of its advantages. There may, however, be an increased risk of graft-versus-host-disease (GVHD) because of the large number of lymphocytes present in a leukapheresis product. An 18-year-old man with severe aplastic anemia underwent an allogeneic BMT using his HLA-identical sister. After initial excellent graft take for 8 months, his blood counts gradually decreased to 2.8 x 10(9)/L of white cells and 28 x 10(9)/L of platelets with marrow cellularity of < 10%. After allogeneic granulocyte-colony stimulating factor mobilized PBSC rescue, the patient's blood counts recovered satisfactorily. Around 1 year after the boost, he developed chronic GVHD that responded to prednisolone and cyclosporin A. He is now well on low-dose steroids at day +1055 after PBSC rescue. The present case is the first experience of a long-term follow-up who underwent allogeneic PBSC rescue in Korea.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9538634      PMCID: PMC4531930          DOI: 10.3904/kjim.1998.13.1.60

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  10 in total

1.  Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors.

Authors:  J A Russell; J Luider; M Weaver; C Brown; S Selinger; C Railton; L Karlsson; J Klassen
Journal:  Bone Marrow Transplant       Date:  1995-01       Impact factor: 5.483

2.  Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation.

Authors:  P Dreger; M Suttorp; T Haferlach; H Löffler; N Schmitz; W Schroyens
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

3.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation.

Authors:  J Nemunaitis; J W Singer; C D Buckner; D Durnam; C Epstein; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

4.  Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia.

Authors:  A Kessinger; D M Smith; S E Strandjord; J D Landmark; D C Dooley; P Law; P F Coccia; P I Warkentin; D D Weisenburger; J O Armitage
Journal:  Bone Marrow Transplant       Date:  1989-11       Impact factor: 5.483

5.  Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation.

Authors:  J Peralvo; A Bacigalupo; P A Pittaluga; D Occhini; M T Van Lint; F Frassoni; E Nardelli; A Transino; M Pantarotto; A M Marmout
Journal:  Bone Marrow Transplant       Date:  1987-10       Impact factor: 5.483

6.  Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation.

Authors:  N H Russell; A Hunter; S Rogers; J Hanley; D Anderson
Journal:  Lancet       Date:  1993-06-05       Impact factor: 79.321

7.  High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.

Authors:  I Majolino; G Saglio; R Scimè; A Serra; A M Cavallaro; T Fiandaca; S Vasta; M Pampinella; P Catania; A Indovina; R Marcenò; A Santoro
Journal:  Bone Marrow Transplant       Date:  1996-04       Impact factor: 5.483

8.  Marrow harvesting from normal donors.

Authors:  C D Buckner; R A Clift; J E Sanders; P Stewart; W I Bensinger; K C Doney; K M Sullivan; R P Witherspoon; H J Deeg; F R Appelbaum
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

9.  Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia.

Authors:  D Niederwieser; M Pepe; R Storb; T P Loughran; G Longton
Journal:  Br J Haematol       Date:  1988-05       Impact factor: 6.998

10.  Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor.

Authors:  C H Weaver; K Longin; C D Buckner; W Bensinger
Journal:  Bone Marrow Transplant       Date:  1994-04       Impact factor: 5.483

  10 in total
  1 in total

1.  Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.

Authors:  Ho Cheol Shin; Yoo Jin Lee; Joon Ho Moon; Soo Jung Lee; Byung Woog Kang; Yee Soo Chae; Jong Gwang Kim; Jun Young Choi; Jong Won Seo; Yu Kyung Kim; Jang Soo Suh; Sang Kyun Sohn
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.